How to Submit to Circulation: Process & Requirements 2026

Circulation is the flagship journal of the American Heart Association and sits among the top three cardiovascular journals globally, alongside JACC and European Heart Journal. It has an IF around 38.6 and publishes primarily clinical cardiology research. If your work has direct implications for cardiovascular clinical practice, this is your target.

Circulation Submission Overview

Circulation's desk rejection rate is about 70-75%. The editorial team is fast: most authors get a desk decision within a week. Papers that reach peer review are accepted at a rate around 40-45%, which is higher than many comparable journals.

Impact factor: 38.6 (2024)

Acceptance rate: ~12-15% overall

Desk rejection rate: ~70-75%

Time to desk decision: 5-10 days

Time to first decision (peer review): 4-6 weeks

What Circulation Publishes

Circulation's scope is cardiovascular medicine broadly:

• Clinical trials (cardiovascular outcomes, device trials, pharmacological)
• Large cohort studies with cardiovascular endpoints
• Basic/translational research with clear cardiovascular relevance
• Systematic reviews and meta-analyses of cardiovascular interventions
• Epidemiology of heart disease, heart failure, arrhythmias, vascular disease

The journal particularly values practice-changing clinical research. If your work reshapes how cardiologists treat a specific condition, that's exactly what Circulation wants. Basic science that doesn't connect to clinical practice tends to go to Circulation Research instead.

Circulation and Circulation Research are distinct journals with different scopes. Circulation covers clinical and translational cardiology. Circulation Research covers mechanisms and basic cardiovascular science. Submit to the right one.

Format Requirements

Circulation uses an online submission system through the AHA Manuscript Central platform.

Research Articles:

• Main text: 4,000 words max (excluding references, figure legends, tables)
• Abstract: 250 words max, structured (background, methods, results, conclusions)
• References: 50 max for Research Articles
• Figures: up to 8 in the main paper; unlimited supplemental material

Research Letters:

• Up to 1,200 words, 2 figures, 15 references
• No abstract required
• Useful for focused findings that don't need a full paper

Required elements for all submissions:

• Structured abstract
• Novelty and Significance statement (what's new + what's clinically significant)
• Clinical Perspective box (2-3 sentences on implications for practice)
• Competing interests form
• Author contributions (CRediT)
• Data sharing statement with repository links where applicable

For clinical trials specifically:

• CONSORT checklist and flow diagram (non-negotiable)
• Trial registration number (must be registered before first patient enrolled)
• Pre-specified primary endpoint stated in Methods

The Cover Letter

Circulation editors read the cover letter first. AHA journals have a specific editorial philosophy: they prioritize cardiovascular health impact, not just scientific interest.

Your cover letter should open with a single sentence on what your study shows, then move immediately to clinical significance: what does this change for patients or practitioners?

Effective structure:

• Sentence 1-2: What you studied and what you found. Specific (include primary endpoint result and p-value or HR if it fits naturally).
• Sentence 3-4: Clinical significance. Which patients benefit? What changes in practice or guidelines?
• Sentence 5-6: Why Circulation specifically? What about the study scope and readership fit?

Keep it under 300 words. Circulation editors don't want a paragraph on why cardiovascular disease is important.

The Novelty and Significance section (separate from the cover letter) also needs serious attention. Editors read it alongside the abstract. It's your one-paragraph case for why this paper is novel and why it matters. Many desk rejections happen because the novelty statement was weak even when the paper itself was solid.

The Desk Review Process

After submission, a handling editor reads your abstract, the first two paragraphs of your introduction, and your figures. They're asking:

1. Is this within Circulation's scope (clinical cardiovascular)?
2. Does the primary endpoint answer an important clinical question?
3. Is the study design sound (randomized, adequately powered, appropriate controls)?
4. Does the abstract clearly state what was done, found, and what it means?
5. Is this clinically significant enough for Circulation's readership?

Circulation editors are generally cardiologists or cardiovascular scientists themselves. They know the clinical field cold. If your work doesn't move the needle for clinical practice, they'll tell you quickly.

Peer Review Stage

Circulation typically uses 2-3 external reviewers. Single-blind. Editors choose reviewers from their own networks and from your suggestions.

Review period: 21-28 days from assignment. Circulation is generally faster than most AHA journals because reviewers tend to engage quickly with clinical cardiology papers.

Possible decisions:

• Accept (rare on first round): less than 5% of papers reaching review
• Minor revision: 15-20%. A near-certain acceptance if you address the comments.
• Major revision: 45-55%. The most common positive outcome.
• Reject with encouragement: 10-15%. Worth resubmitting if the specific concerns can be addressed with new data.
• Reject: 20-25%.

Major revisions at Circulation often ask for:

• Additional subgroup analyses
• Sensitivity analyses with different covariate adjustments
• Clarification of whether endpoints were pre-specified or exploratory
• Updated literature review to address recent publications in the same area

Revision window is 60 days for major revisions; extensions available on request.

Statistics and Reporting

Circulation has strict statistical standards, especially for clinical trials. Common issues:

• Multiple comparisons: If you tested multiple secondary endpoints, you need to address multiplicity explicitly. Pre-specified primary endpoints can stand alone; exploratory analyses need correction or at minimum disclosure as exploratory.
• P-values vs. confidence intervals: Circulation increasingly prefers effect sizes with confidence intervals over just p-values. Report both.
• Missing data: Imputation strategy must be stated. Complete case analysis without justification is flagged routinely.
• Kaplan-Meier figures: Required for time-to-event data; must show numbers at risk at each time interval.

If your paper has a statistician author or acknowledgment, that helps signal rigor. If it doesn't, make sure your statistical methods paragraph is thorough enough to stand on its own.

Common Desk Rejection Reasons

Insufficient clinical relevance: Great mechanistic data with no direct patient or practice implication. The editor won't send it out for review.

Underpowered study: Small clinical trials or observational studies without adequate sample sizes to detect meaningful differences. Circulation has no interest in underpowered trials, regardless of direction.

Secondary publication concerns: Any overlap with previously published work, even in conference proceedings, needs to be disclosed. Editors check.

Not CONSORT-compliant: Missing trial registration, missing flow diagram, or not reporting per CONSORT standards.

Scope mismatch: Sending a basic science cardiovascular paper to Circulation instead of Circulation Research. Both are excellent journals but they're genuinely different.

How to Write the Novelty and Significance Statement

The Novelty and Significance section is required for all Circulation submissions. Editors read it before the abstract. Many desk rejections happen because this section is vague even when the paper itself is solid.

The section has two parts: "What Is New" and "What Are the Clinical Implications."

"What Is New" should contain 3-5 bullet points. Each bullet states a single new finding with specifics. Not "we show that treatment X improves outcomes in patients with Y" but "in a randomized trial of 1,240 patients with Y, treatment X reduced the primary endpoint (composite of cardiovascular death and hospitalization for heart failure) by 22% over 24 months."

Include numbers. Editors reviewing hundreds of submissions need to see the magnitude of your findings in 10 seconds.

"What Are the Clinical Implications" should have 2-3 bullet points. Each one directly connects your finding to what a cardiologist does in practice. Not "these findings have implications for clinical practice" but "patients with Y who are currently receiving standard of care X should be considered for treatment Z pending guideline updates."

Common problems to avoid:

• Bullets that describe methods instead of findings: "We conducted a multicenter RCT..." is not novel.
• Implications that are too generic: "this supports further research" isn't an implication.
• Missing effect sizes: an editor can't evaluate significance without scale.

Write this section after the paper is done. Use it to force yourself to articulate the two or three things that make this paper worth 10 minutes of a busy cardiologist's time.

What the AHA Editorial Philosophy Means in Practice

Circulation is the American Heart Association's flagship publication. That institutional identity shapes editorial decisions in specific, practical ways.

The AHA's mission is "to be a relentless force for a world of longer, healthier lives." Circulation's editorial team takes this seriously. Papers that address underrepresented populations or study conditions with high cardiovascular burden in low-resource settings receive genuine attention.

What this means practically:

Studies in diverse populations are valued. If your trial or cohort includes meaningful representation from historically underrepresented groups, make that explicit in your abstract and Novelty statement. Editors are actively interested in whether findings generalize beyond the populations in which most cardiovascular research has been conducted.

Practice-changing evidence is prioritized over statistical novelty. A modestly-sized but well-designed trial that definitively resolves a clinical question will be reviewed ahead of a large observational dataset showing a small association.

Guideline relevance matters. If your findings are relevant to AHA or ACC guideline recommendations, say so specifically. Which class of recommendation would change? Which patient population? Editors who serve on guideline committees notice this.

Industry-funded trials receive extra scrutiny. The AHA's public health orientation means editors are alert to framing that benefits sponsors. If your trial is industry-sponsored, make sure your primary endpoint and analytic plan are pre-specified and that all sensitivity analyses are disclosed transparently.

Targeting Circulation? Get Pre-Submission Feedback First

The Bottom Line

Circulation's submission requirements are standard for a high-IF cardiology journal. The challenge isn't the process , it's ensuring your paper's scope and evidence level match what Circulation publishes. Strong methods and clear clinical implications are table stakes. The framing needs to match the journal's editorial direction.

Sources

• Journal official submission guidelines
• Author experience data compiled from journal tracker communities (SciRev, Researcher.Life)
• Editorial policies published on journal homepage
• Pre-Submission Checklist , 25-point audit before you submit

See also

• European Heart Journal overview
• Science Advances Submission Process
• How to Write a Journal Cover Letter